Table 3 ICU management and outcome data
From: Severe varicella-zoster virus pneumonia: a multicenter cohort study
Variables | |
|---|---|
VZV-related treatment | |
Aciclovir | 102 (100%) |
Aciclovir dose, mg/8 h | 10 (10–10) |
Steroids | 10 (10%) |
Immunoglobulins | 1 (1%) |
Systemic antibiotics at ICU admission | 62 (61%) |
Primary source of bacterial co-infection (n = 40, 39%) | |
Lung | 24 (60%) |
Bloodstream | 8 (20%) |
Skin | 4 (10%) |
Other | 4 (10%) |
Life-sustaining therapies | |
Non-invasive mechanical ventilation | 29 (28%) |
Invasive mechanical ventilation | 52 (51%) |
Vasopressors | 36 (35%) |
Renal replacement therapy | 24 (24%) |
ARDS criteria according to the Berlin definition (n = 42, 41%) | |
Mild ARDS | 8 (19%) |
Moderate ARDS | 10 (24%) |
Severe ARDS | 24 (57%) |
Other interventions | |
Neuromuscular blockers | 26/52 (50%) |
Prone positioning | 14/52 (28%) |
Veno-venous ECMO | 7/52 (13%) |
Outcome data | |
ICU length of stay (days) | 8 (4–16.75) |
Hospital length of stay (days) | 14 (9–33) |
ICU mortality | 17 (17%) |
Hospital mortality | 24 (24%) |